ArticleBritish journal of pharmacology2023
Cannabinoid 1 (CB
Article in British journal of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Cannabinoid tolerance relies on CBProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Side-Chain Homologs of ΔMolecular neurobiology · 2026Article
- AB-MDMSBA-Not a Synthetic Cannabinoid Receptor Agonist.Pharmacology research & perspectives · 2026Article
- Canonical Cannabinoid Receptors.Current topics in behavioral neurosciences · 2026Review
- Article
- CB1 receptor coupling to extracellular regulated kinase via multiple Gαi/o isoforms.Neuroreport · 2025Article
- Determination of the Cannabinoid CB1 Receptor's Positive Allosteric Modulator Binding Site through Mutagenesis Studies.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.ACS chemical neuroscience · 2023Article
- Cannabinoid 1 (CBBritish journal of pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeArrestin or G protein bias may be desirable for novel cannabinoid therapeutics. Arrestin-2 and arrestin-3 translocation to CB EXPERIMENTAL APPROACH: Site-directed mutagenesis was conducted to generate nine different phosphorylation-impaired CB KEY
resultsThe effects of each mutation were shared for arrestin-2 and arrestin-3 translocation to CB CONCLUSIONS AND IMPLICATIONS: These data do not support the existence of an 'essential' pxxp motif for arrestin translocation to CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.